Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | BAX | Q07812 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11742595 | 0.84 | EPHX2 (0.39) | LTA4HTSHRKCNA3MAPTLMNA | |
| SCHEMBL28710286 | 0.80 | LTA4H (0.47) | LTA4HLMNAHTT | |
| SCHEMBL31106429 | 0.80 | LTA4H (0.47) | LTA4HLMNAHTT | |
| SCHEMBL8601466 | 0.80 | LTA4H (0.47) | LTA4HLMNAHTT | |
| SCHEMBL11301704 | 0.79 | TAAR1 (0.41) | LTA4HTSHRKCNA3AOC3 | |
| SCHEMBL29653962 | 0.79 | LTA4H (0.46) | LTA4HLMNAHTT | |
| SCHEMBL13918233 | 0.77 | KCNA3 (0.58) | LTA4HKCNA3HTR1B | |
| SCHEMBL13639157 | 0.76 | KCNA3 (0.61) | LTA4HKCNA3HTR1B | |
| SCHEMBL30071999 | 0.76 | CA4 (0.38) | LTA4HTSHRKCNA3CA4HTR1B | |
| SCHEMBL5898125 | 0.75 | CA4 (0.43) | LTA4HTSHRKCNA3NR1H2BAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785655-B2 | Ionic liquid solvents | DUBLIN CITY UNIVERSITY (IE) | 2014-07-22 | — | — | US | disclosed |
| US-20120071661-A1 | Ionic Liquid Solvents | DUBLIN CITY UNIVERSITY (IE) | 2012-03-22 | — | — | US | disclosed |
| EP-2401258-A1 | IONIC LIQUID SOLVENTS | Dublin City University (IE) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097412-A1 | IONIC LIQUID SOLVENTS | DUBLIN CITY UNIVERSITY (IE) | 2010-09-02 | — | — | WO | disclosed |
| EP-2223915-A1 | Ionic liquid solvents | Dublin City University (IE) | 2010-09-01 | — | — | EP | disclosed |
| EP-1165477-A1 | METHOD FOR PRODUCING ALKAPOLYENYL COMPOUNDS USING CERTAIN COCATALYSTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059854-A1 | METHOD FOR PRODUCING ALKAPOLYENYL COMPOUNDS USING CERTAIN COCATALYSTS | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071661-A1 | Ionic Liquid Solvents | EBP, PAICS, HACD3 | LTA4H 238/4885TSHR 4680/4885KCNA3 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.